Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.

JHEP reports : innovation in hepatology

Nevens F, Gustot T, Laterre PF, Lasser LL, Haralampiev LE, Vargas V, Lyubomirova D, Albillos A, Najimi M, Michel S, Stoykov I, Gordillo N, Vainilovich Y, Barthel V, Clerget-Chossat N, Sokal EM.
PMID: 34169246
JHEP Rep. 2021 Apr 18;3(4):100291. doi: 10.1016/j.jhepr.2021.100291. eCollection 2021 Aug.

BACKGROUND & AIMS: Human allogeneic liver-derived progenitor cells (HALPC, HepaStem®; Promethera Biosciences, Mont-Saint-Guibert, Belgium) are an advanced therapy medicinal product that could potentially alleviate systemic inflammation and ameliorate liver function in patients with acute-on-chronic liver failure (ACLF) or acute...

Cite
Nevens F, Gustot T, Laterre PF, et al. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Rep. 2021;3(4):100291doi: 10.1016/j.jhepr.2021.100291.
Nevens, F., Gustot, T., Laterre, P. F., Lasser, L. L., Haralampiev, L. E., Vargas, V., Lyubomirova, D., Albillos, A., Najimi, M., Michel, S., Stoykov, I., Gordillo, N., Vainilovich, Y., Barthel, V., Clerget-Chossat, N., & Sokal, E. M. (2021). A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP reports : innovation in hepatology, 3(4), 100291. https://doi.org/10.1016/j.jhepr.2021.100291
Nevens, Frederik, et al. "A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation." JHEP reports : innovation in hepatology vol. 3,4 (2021): 100291. doi: https://doi.org/10.1016/j.jhepr.2021.100291
Nevens F, Gustot T, Laterre PF, Lasser LL, Haralampiev LE, Vargas V, Lyubomirova D, Albillos A, Najimi M, Michel S, Stoykov I, Gordillo N, Vainilovich Y, Barthel V, Clerget-Chossat N, Sokal EM. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Rep. 2021 Apr 18;3(4):100291. doi: 10.1016/j.jhepr.2021.100291. eCollection 2021 Aug. PMID: 34169246; PMCID: PMC8207211.
Copy Download .nbib Format: NLM
Injected Human Muscle Precursor Cells Overexpressing PGC-1.

Stem cells international

Haralampieva D, Salemi S, Betzel T, Dinulovic I, Krämer SD, Schibli R, Sulser T, Handschin C, Ametamey SM, Eberli D.
PMID: 29531537
Stem Cells Int. 2018 Jan 21;2018:4658503. doi: 10.1155/2018/4658503. eCollection 2018.

While many groups demonstrated new muscle tissue formation after muscle precursor cell (MPC) injection, the capacity of these cells to heal muscle damage, for example, sphincter in stress urinary incontinence, in long-term is still limited. Therefore, the first goal...

Cite
Haralampieva D, Salemi S, Betzel T, et al. Injected Human Muscle Precursor Cells Overexpressing PGC-1. Stem Cells Int. 2018;2018:4658503doi: 10.1155/2018/4658503.
Haralampieva, D., Salemi, S., Betzel, T., Dinulovic, I., Krämer, S. D., Schibli, R., Sulser, T., Handschin, C., Ametamey, S. M., & Eberli, D. (2018). Injected Human Muscle Precursor Cells Overexpressing PGC-1. Stem cells international, 20184658503. https://doi.org/10.1155/2018/4658503
Haralampieva, Deana, et al. "Injected Human Muscle Precursor Cells Overexpressing PGC-1." Stem cells international vol. 2018 (2018): 4658503. doi: https://doi.org/10.1155/2018/4658503
Haralampieva D, Salemi S, Betzel T, Dinulovic I, Krämer SD, Schibli R, Sulser T, Handschin C, Ametamey SM, Eberli D. Injected Human Muscle Precursor Cells Overexpressing PGC-1. Stem Cells Int. 2018 Jan 21;2018:4658503. doi: 10.1155/2018/4658503. eCollection 2018. PMID: 29531537; PMCID: PMC5827889.
Copy Download .nbib Format: NLM
Membrane properties of hydroxycholesterols related to the brain cholesterol metabolism.

Beilstein journal of organic chemistry

Hilsch M, Haralampiev I, Müller P, Huster D, Scheidt HA.
PMID: 28503207
Beilstein J Org Chem. 2017 Apr 18;13:720-727. doi: 10.3762/bjoc.13.71. eCollection 2017.

Compared to cholesterol, hydroxycholesterols contain an additional hydroxy group in the alkyl chain and are able to efficiently cross the brain-blood barrier. Therefore, they are responsible for the sterol transfer between brain and circulation. The current study compares the...

Cite
Hilsch M, Haralampiev I, Müller P, et al. Membrane properties of hydroxycholesterols related to the brain cholesterol metabolism. Beilstein J Org Chem. 2017;13:720-727doi: 10.3762/bjoc.13.71.
Hilsch, M., Haralampiev, I., Müller, P., Huster, D., & Scheidt, H. A. (2017). Membrane properties of hydroxycholesterols related to the brain cholesterol metabolism. Beilstein journal of organic chemistry, 13720-727. https://doi.org/10.3762/bjoc.13.71
Hilsch, Malte, et al. "Membrane properties of hydroxycholesterols related to the brain cholesterol metabolism." Beilstein journal of organic chemistry vol. 13 (2017): 720-727. doi: https://doi.org/10.3762/bjoc.13.71
Hilsch M, Haralampiev I, Müller P, Huster D, Scheidt HA. Membrane properties of hydroxycholesterols related to the brain cholesterol metabolism. Beilstein J Org Chem. 2017 Apr 18;13:720-727. doi: 10.3762/bjoc.13.71. eCollection 2017. PMID: 28503207; PMCID: PMC5405690.
Copy Download .nbib Format: NLM
A mass casualty incident of infectious diseases at the port of Hamburg: an analysis of organizational structures and emergency concepts.

Journal of occupational medicine and toxicology (London, England)

Klein A, Heuser J, Henning E, Sprössel N, Kordsmeyer AC, Oldenburg M, Mojtahedzadeh N, Heidrich J, Militzer KC, Belz L, von Münster T, Harth V, Ehlers L, de Boer J, Kleine-Kampmann S, Boldt M, Dirksen-Fischer M, Haralambiev L, Gümbel D, Ekkernkamp A, Bakir MS.
PMID: 34465347
J Occup Med Toxicol. 2021 Aug 31;16(1):36. doi: 10.1186/s12995-021-00324-0.

BACKGROUND: The project "ARMIHN" (Adaptive Resiliency Management in Port) focuses on strengthening the capability to act in a mass casualty incident (MCI) due to an outbreak of infectious diseases (MCI-ID). In addition to the current threat from the COVID-19...

Cite
Klein A, Heuser J, Henning E, et al. A mass casualty incident of infectious diseases at the port of Hamburg: an analysis of organizational structures and emergency concepts. J Occup Med Toxicol. 2021;16(1):36doi: 10.1186/s12995-021-00324-0.
Klein, A., Heuser, J., Henning, E., Sprössel, N., Kordsmeyer, A. C., Oldenburg, M., Mojtahedzadeh, N., Heidrich, J., Militzer, K. C., Belz, L., von Münster, T., Harth, V., Ehlers, L., de Boer, J., Kleine-Kampmann, S., Boldt, M., Dirksen-Fischer, M., Haralambiev, L., Gümbel, D., Ekkernkamp, A., & Bakir, M. S. (2021). A mass casualty incident of infectious diseases at the port of Hamburg: an analysis of organizational structures and emergency concepts. Journal of occupational medicine and toxicology (London, England), 16(1), 36. https://doi.org/10.1186/s12995-021-00324-0
Klein, Angelina, et al. "A mass casualty incident of infectious diseases at the port of Hamburg: an analysis of organizational structures and emergency concepts." Journal of occupational medicine and toxicology (London, England) vol. 16,1 (2021): 36. doi: https://doi.org/10.1186/s12995-021-00324-0
Klein A, Heuser J, Henning E, Sprössel N, Kordsmeyer AC, Oldenburg M, Mojtahedzadeh N, Heidrich J, Militzer KC, Belz L, von Münster T, Harth V, Ehlers L, de Boer J, Kleine-Kampmann S, Boldt M, Dirksen-Fischer M, Haralambiev L, Gümbel D, Ekkernkamp A, Bakir MS. A mass casualty incident of infectious diseases at the port of Hamburg: an analysis of organizational structures and emergency concepts. J Occup Med Toxicol. 2021 Aug 31;16(1):36. doi: 10.1186/s12995-021-00324-0. PMID: 34465347; PMCID: PMC8406386.
Copy Download .nbib Format: NLM
Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used.

Oncology letters

Haralambiev L, Wien L, Gelbrich N, Lange J, Bakir S, Kramer A, Burchardt M, Ekkernkamp A, Gümbel D, Stope MB.
PMID: 31897140
Oncol Lett. 2020 Jan;19(1):283-290. doi: 10.3892/ol.2019.11115. Epub 2019 Nov 19.

Osteosarcoma (OS) is the most common tumor of the musculoskeletal system. Recently, cold atmospheric plasma (CAP) has been regarded as a promising anti-oncogenic therapy. Previous experimental studies have demonstrated that CAP treatment results in significant growth inhibition of human...

Cite
Haralambiev L, Wien L, Gelbrich N, et al. Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used. Oncol Lett. 2019;19(1):283-290doi: 10.3892/ol.2019.11115.
Haralambiev, L., Wien, L., Gelbrich, N., Lange, J., Bakir, S., Kramer, A., Burchardt, M., Ekkernkamp, A., Gümbel, D., & Stope, M. B. (2020). Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used. Oncology letters, 19(1), 283-290. https://doi.org/10.3892/ol.2019.11115
Haralambiev, Lyubomir, et al. "Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used." Oncology letters vol. 19,1 (2020): 283-290. doi: https://doi.org/10.3892/ol.2019.11115
Haralambiev L, Wien L, Gelbrich N, Lange J, Bakir S, Kramer A, Burchardt M, Ekkernkamp A, Gümbel D, Stope MB. Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used. Oncol Lett. 2020 Jan;19(1):283-290. doi: 10.3892/ol.2019.11115. Epub 2019 Nov 19. PMID: 31897140; PMCID: PMC6924118.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries